Clinical Data Boehringer advances duo for aggressive cancers into phase 3 PharmaphorumBoehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.OncologyRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Insilico and SK Bio forge $2.5bn AI neuroimmunity allianceNext: Lilly bets up to $800M for BioArctic’s brain delivery tech Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
